{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:37:36Z","timestamp":1791841056524,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dengue virus (DENV) has emerged as a formidable global health challenge, with a surging incidence rate across the world. Despite numerous research initiatives aimed at developing effective antiviral therapy, no clinically proven drug or vaccine has been identified to combat all four genetically diverse serotypes of DENV. Therefore, comparative analysis of repurposed drugs and phytocompounds against all DENV serotypes is critical in the search for an effective long-term solution to this menacing disease. 93 phytocompounds and 15 drugs were shortlisted from the literature and screened using DataWarrior 5.5.0, from which 10 phytocompounds and 10 drugs were selected for further analysis. Molecular docking was performed by using AutoDockVina tool. Toxicity and druglikeness activity of standard drugs and phytoconstituents was done by using online servers. The current study showed that among all the selected phytoconstituents, lupiwighteone showed the best binding energy, favorable pharmacokinetics and no toxicity with all the selected serotypes of DENV. The MD simulation result supported the stability of lupiwighteone in complexes with NS3, NS5 and E-protein. This study identifies lupiwighteone as a promising antiviral candidate with favorable drug-like properties against DENV-2, DENV-3, and DENV-4 serotypes. Furthermore, in vitro and in vivo study is required for the validation of antiviral activity of lupiwighteone against dengue virus.<\/jats:p>","DOI":"10.1038\/s41598-025-06974-y","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:51:18Z","timestamp":1753912278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative analysis of phytocompounds and repurposed drugs against dengue virus serotypes employing an in silico study"],"prefix":"10.1038","volume":"15","author":[{"given":"Pranjal","family":"Vats","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Rolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Salaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatomide A.","family":"Fadare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"6974_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.gene.2019.02.001","volume":"695","author":"M Verma","year":"2019","unstructured":"Verma, M. et al. Highly conserved epitopes of DENV structural and non-structural proteins: Candidates for universal vaccine targets. Gene 695, 18\u201325. https:\/\/doi.org\/10.1016\/j.gene.2019.02.001 (2019).","journal-title":"Gene"},{"key":"6974_CR2","doi-asserted-by":"publisher","unstructured":"Murugesan, A. & Manoharan, M. Dengue virus. In Emerging Reemerging Viral Pathogens 281\u2013359. https:\/\/doi.org\/10.1016\/B978-0-12-819400-3.00016-8 (2020).","DOI":"10.1016\/B978-0-12-819400-3.00016-8"},{"key":"6974_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1128\/CMR.11.3.480","volume":"11","author":"DJ Gubler","year":"1998","unstructured":"Gubler, D. J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11, 480\u2013496 (1998).","journal-title":"Clin. Microbiol. Rev."},{"key":"6974_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504\u2013507. https:\/\/doi.org\/10.1038\/nature12060 (2013).","journal-title":"Nature"},{"key":"6974_CR5","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/nrmicro2460","volume":"8","author":"MG Guzman","year":"2010","unstructured":"Guzman, M. G. et al. Dengue: A continuing global threat. Nat. Rev. Microbiol. 8, S7\u2013S16. https:\/\/doi.org\/10.1038\/nrmicro2460 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"6974_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/978-3-030-71165-8_19","volume-title":"Human Viruses: Diseases, Treatments and Vaccines: The New Insights","author":"M Verma","year":"2021","unstructured":"Verma, M., Phartyal, R. & Bhatt, A. Introduction to flaviviruses and their global prevalence. In Human Viruses: Diseases, Treatments and Vaccines: The New Insights (ed Ahmad, S. I.) 411\u2013439 (Springer International Publishing, 2021). https:\/\/doi.org\/10.1007\/978-3-030-71165-8_19."},{"key":"6974_CR7","doi-asserted-by":"publisher","first-page":"106501","DOI":"10.1016\/j.actatropica.2022.106501","volume":"232","author":"A Jaglan","year":"2022","unstructured":"Jaglan, A., Satija, S., Singh, D., Phartyal, R. & Verma, M. Intra-genomic heterogeneity in CpG dinucleotide composition in dengue virus. Acta Trop. 232, 106501. https:\/\/doi.org\/10.1016\/j.actatropica.2022.106501 (2022).","journal-title":"Acta Trop."},{"key":"6974_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","volume":"15","author":"SJ Thomas","year":"2019","unstructured":"Thomas, S. J. & Yoon, I-K. A review of Dengvaxia\u00ae: Development to deployment. Hum. Vaccines Immunother. 15, 2295\u20132314. https:\/\/doi.org\/10.1080\/21645515.2019.1658503 (2019).","journal-title":"Hum. Vaccin Immunother"},{"key":"6974_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.antiviral.2015.04.010","volume":"119","author":"SP Lim","year":"2015","unstructured":"Lim, S. P., Noble, C. G. & Shi, P-Y. The dengue virus NS5 protein as a target for drug discovery. Antiviral Res. 119, 57\u201367. https:\/\/doi.org\/10.1016\/j.antiviral.2015.04.010 (2015).","journal-title":"Antiviral Res."},{"key":"6974_CR10","doi-asserted-by":"publisher","first-page":"113527","DOI":"10.1016\/j.ejmech.2021.113527","volume":"221","author":"SAH Pujar","year":"2021","unstructured":"Pujar, S. A. H., Sethu, G. V., Bhagyalalitha, A. K. & Singh, M. Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development. Eur. J. Med. Chem. 221, 113527. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113527 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"6974_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10096-018-3375-7","volume":"38","author":"S Sukhralia","year":"2019","unstructured":"Sukhralia, S. et al. From dengue to zika: The wide spread of mosquito-borne arboviruses. Eur. J. Clin. Microbiol. Infect. Dis. 38, 3\u201314. https:\/\/doi.org\/10.1007\/s10096-018-3375-7 (2019).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"6974_CR12","doi-asserted-by":"publisher","first-page":"msad033","DOI":"10.1093\/molbev\/msad033","volume":"40","author":"A Sharma","year":"2023","unstructured":"Sharma, A., Krishna, S. & Sowdhamini, R. Bioinformatics analysis of mutations sheds light on the evolution of dengue NS1 protein with implications in the identification of potential functional and druggable sites. Mol. Biol. Evol. 40, msad033. https:\/\/doi.org\/10.1093\/molbev\/msad033 (2023).","journal-title":"Mol. Biol. Evol."},{"key":"6974_CR13","doi-asserted-by":"publisher","first-page":"14131","DOI":"10.1080\/07391102.2021.2001371","volume":"40","author":"D Salaria","year":"2022","unstructured":"Salaria, D. et al. In vitro and in Silico antioxidant and anti-inflammatory potential Of essential oil of Cymbopogon citratus (DC.) stapf. Of North-Western Himalaya. J. Biomol. Struct. Dyn. 40, 14131\u201314145. https:\/\/doi.org\/10.1080\/07391102.2021.2001371 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"6974_CR14","doi-asserted-by":"publisher","first-page":"e0265420","DOI":"10.1371\/journal.pone.0265420","volume":"17","author":"D Salaria","year":"2022","unstructured":"Salaria, D. et al. Phytoconstituents of traditional Himalayan herbs as potential inhibitors of human papillomavirus (HPV-18) for cervical cancer treatment: An in silico approach. PLoS One. 17, e0265420. https:\/\/doi.org\/10.1371\/journal.pone.0265420 (2022).","journal-title":"PLoS One"},{"key":"6974_CR15","doi-asserted-by":"publisher","first-page":"10383","DOI":"10.1080\/07391102.2021.1943530","volume":"40","author":"D Salaria","year":"2022","unstructured":"Salaria, D. et al. In vitro and in silico analysis of Thymus serpyllum essential oil as bioactivity enhancer of antibacterial and antifungal agents. J. Biomol. Struct. Dyn. 40, 10383\u201310402. https:\/\/doi.org\/10.1080\/07391102.2021.1943530 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"6974_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40495-021-00259-4","volume":"7","author":"R Rolta","year":"2021","unstructured":"Rolta, R. et al. Phytocompounds of Rheum emodi, Thymus serpyllum, and Artemisia annua inhibit spike protein of SARS-CoV-2 binding to ACE2 receptor: in silico approach. Curr. Pharmacol. Rep. 7, 135\u2013149. https:\/\/doi.org\/10.1007\/s40495-021-00259-4 (2021).","journal-title":"Curr. Pharmacol. Rep."},{"key":"6974_CR17","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1080\/07391102.2020.1850364","volume":"40","author":"R Rolta","year":"2022","unstructured":"Rolta, R. et al. Molecular Docking studies of phytocompounds of Rheum emodi wall with proteins responsible for antibiotic resistance in bacterial and fungal pathogens: in Silico approach to enhance the bio-availability of antibiotics. J. Biomol. Struct. Dyn. 40, 3789\u20133803. https:\/\/doi.org\/10.1080\/07391102.2020.1850364 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"6974_CR18","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1080\/07391102.2024.2305313","volume":"43","author":"R Rolta","year":"2025","unstructured":"Rolta, R. et al. Identification of novel inhibitor phytoconstituents for influenza A H3N2: An in silico approach. J. Biomol. Struct. Dyn. 43, 4287\u20134296. https:\/\/doi.org\/10.1080\/07391102.2024.2305313 (2025).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"6974_CR19","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.3390\/molecules27154971","volume":"27","author":"J Mehta","year":"2022","unstructured":"Mehta, J. et al. Antibacterial potential of Bacopa monnieri (L.) wettst. and its bioactive molecules against Uropathogens\u2014An in Silico study to identify potential lead Molecule(s) for the development of new drugs to treat urinary tract infections. Molecules 27, 4971. https:\/\/doi.org\/10.3390\/molecules27154971 (2022).","journal-title":"Molecules"},{"key":"6974_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/biomedicines9101402","volume":"9","author":"J Mehta","year":"2021","unstructured":"Mehta, J. et al. Phytocompounds from Himalayan medicinal plants as potential drugs to treat multidrug-resistant Salmonella typhimurium: An in silico approach. Biomedicines 9, 1402. https:\/\/doi.org\/10.3390\/biomedicines9101402 (2021).","journal-title":"Biomedicines"},{"key":"6974_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13205-022-03450-6","volume":"13","author":"A Chugh","year":"2023","unstructured":"Chugh, A. et al. Comparative Docking studies of drugs and phytocompounds for emerging variants of SARS-CoV-2. 3 Biotech 13, 36. https:\/\/doi.org\/10.1007\/s13205-022-03450-6 (2023).","journal-title":"3 Biotech."},{"key":"6974_CR22","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.3390\/molecules27134077","volume":"27","author":"B Kaur","year":"2022","unstructured":"Kaur, B. et al. An in Silico investigation to explore Anti-Cancer potential of Foeniculum vulgare mill. Phytoconstituents for the management of human breast Cancer. Molecules 27, 4077. https:\/\/doi.org\/10.3390\/molecules27134077 (2022).","journal-title":"Molecules"},{"key":"6974_CR23","unstructured":"Purohit, P., Dash, J. J. & Meher, B. Exploration of phytocompounds as potential anti-dengue agents against Denv Ns2b-Ns3 protease: Structure-based virtual screening and Md simulation studies (2020)."},{"key":"6974_CR24","doi-asserted-by":"publisher","first-page":"100932","DOI":"10.1016\/j.imu.2022.100932","volume":"30","author":"M Hasan","year":"2022","unstructured":"Hasan, M., Mia, M. M., Munna, S. U., Talha, M. M. H. & Das, K. Seawater fungi-derived compound screening to identify novel small molecules against dengue virus NS5 methyltransferase and NS2B\/NS3 protease. Inf. Med. Unlocked 30, 100932. https:\/\/doi.org\/10.1016\/j.imu.2022.100932 (2022).","journal-title":"Inf. Med. Unlocked"},{"key":"6974_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/v12040367","volume":"12","author":"MI Anasir","year":"2020","unstructured":"Anasir, M. I., Ramanathan, B. & Poh, C. L. Structure-Based design of antivirals against envelope glycoprotein of dengue virus. Viruses 12, 367. https:\/\/doi.org\/10.3390\/v12040367 (2020).","journal-title":"Viruses"},{"key":"6974_CR26","doi-asserted-by":"publisher","first-page":"129623","DOI":"10.1016\/j.bmcl.2024.129623","volume":"99","author":"C-S Lin","year":"2024","unstructured":"Lin, C-S. et al. Inhibition of dengue viruses by N-methylcytisine Thio derivatives through targeting viral envelope protein and NS2B-NS3 protease. Bioorg. Med. Chem. Lett. 99, 129623. https:\/\/doi.org\/10.1016\/j.bmcl.2024.129623 (2024).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"6974_CR27","doi-asserted-by":"publisher","first-page":"e0007894","DOI":"10.1371\/journal.pntd.0007894","volume":"13","author":"H Shimizu","year":"2019","unstructured":"Shimizu, H. et al. Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent RNA polymerase. PLoS Negl. Trop. Dis. 13, e0007894. https:\/\/doi.org\/10.1371\/journal.pntd.0007894 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"6974_CR28","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.3390\/ijms25084376","volume":"25","author":"J Starvaggi","year":"2024","unstructured":"Starvaggi, J., Previti, S., Zappal\u00e0, M. & Ettari, R. The Inhibition of NS2B\/NS3 protease: A new therapeutic opportunity to treat dengue and Zika virus infection. Int. J. Mol. Sci. 25, 4376. https:\/\/doi.org\/10.3390\/ijms25084376 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"6974_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1128\/JVI.01788-07","volume":"82","author":"D Luo","year":"2008","unstructured":"Luo, D. et al. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 82, 173\u2013183. https:\/\/doi.org\/10.1128\/JVI.01788-07 (2008).","journal-title":"J. Virol."},{"key":"6974_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nsmb1073","volume":"13","author":"P Erbel","year":"2006","unstructured":"Erbel, P. et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West nile virus. Nat. Struct. Mol. Biol. 13, 372\u2013373. https:\/\/doi.org\/10.1038\/nsmb1073 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"6974_CR31","doi-asserted-by":"publisher","first-page":"e1004682","DOI":"10.1371\/journal.ppat.1004682","volume":"11","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. A crystal structure of the dengue virus NS5 protein reveals a novel inter-domain interface essential for protein flexibility and virus replication. PLoS Pathog. 11, e1004682. https:\/\/doi.org\/10.1371\/journal.ppat.1004682 (2015).","journal-title":"PLoS Pathog"},{"key":"6974_CR32","doi-asserted-by":"publisher","first-page":"e01294","DOI":"10.1128\/JVI.01294-19","volume":"94","author":"A El Sahili","year":"2019","unstructured":"El Sahili, A. et al. NS5 from dengue virus serotype 2 can adopt a conformation analogous to that of its Zika virus and Japanese encephalitis virus homologues. J. Virol. 94, e01294\u2013e01219. https:\/\/doi.org\/10.1128\/JVI.01294-19 (2019).","journal-title":"J. Virol."},{"key":"6974_CR33","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1073\/pnas.0832193100","volume":"100","author":"Y Modis","year":"2003","unstructured":"Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100, 6986\u20136991. https:\/\/doi.org\/10.1073\/pnas.0832193100 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"6974_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"6974_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/wcms.1127","volume":"3","author":"JG Frey","year":"2013","unstructured":"Frey, J. G. & Bird, C. L. Cheminformatics and the semantic web: Adding value with linked data and enhanced provenance. Wiley Interdiscip. Rev. Comput. Mol. Sci. 3, 465\u2013481. https:\/\/doi.org\/10.1002\/wcms.1127 (2013).","journal-title":"Wiley Interdiscip Rev. Comput. Mol. Sci."},{"key":"6974_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325. https:\/\/doi.org\/10.1016\/j.softx.2015.06.001 (2015).","journal-title":"SoftwareX"},{"key":"6974_CR37","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Valiente, P. A. & Moreno, E. gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 17, 6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"6974_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00894-022-05355-w","volume":"28","author":"P Purohit","year":"2022","unstructured":"Purohit, P., Sahoo, S., Panda, M., Sahoo, P. S. & Meher, B. R. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: Structure-based virtual screening, molecular Docking and molecular dynamics simulation studies. J. Mol. Model. 28, 365. https:\/\/doi.org\/10.1007\/s00894-022-05355-w (2022).","journal-title":"J. Mol. Model."},{"key":"6974_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/jcb.30440","volume":"124","author":"JSL Magdaleno","year":"2023","unstructured":"Magdaleno, J. S. L. et al. Toward \u03b1-1,3\/4 fucosyltransferases targeted drug discovery: In Silico Uncovering of promising natural inhibitors of fucosyltransferase 6. J. Cell. Biochem. 124, 1173\u20131185. https:\/\/doi.org\/10.1002\/jcb.30440 (2023).","journal-title":"J. Cell. Biochem."},{"key":"6974_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bmb\/ldq019","volume":"95","author":"J Whitehorn","year":"2010","unstructured":"Whitehorn, J. & Farrar, J. Dengue Br. Med. Bull. 95, 161\u2013173. https:\/\/doi.org\/10.1093\/bmb\/ldq019 (2010).","journal-title":"Br. Med. Bull."},{"key":"6974_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.meegid.2009.02.003","volume":"9","author":"SC Weaver","year":"2009","unstructured":"Weaver, S. C. & Vasilakis, N. Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect. Genet. Evol. 9, 523\u2013540. https:\/\/doi.org\/10.1016\/j.meegid.2009.02.003 (2009).","journal-title":"Infect. Genet. Evol."},{"key":"6974_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.meegid.2018.04.032","volume":"62","author":"S Pollett","year":"2018","unstructured":"Pollett, S. et al. Understanding dengue virus evolution to support epidemic surveillance and counter-measure development. Infect. Genet. Evol. 62, 279\u2013295. https:\/\/doi.org\/10.1016\/j.meegid.2018.04.032 (2018).","journal-title":"Infect. Genet. Evol."},{"key":"6974_CR43","doi-asserted-by":"crossref","unstructured":"Izmirly, A. M., Alturki, S. O., Alturki, S. O., Connors, J. & Haddad, E. K. Challenges in dengue vaccines development: Pre-existing infections and cross-reactivity. Front. Immunol. 11 (2020).","DOI":"10.3389\/fimmu.2020.01055"},{"key":"6974_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","volume":"36","author":"JM Torres-Flores","year":"2022","unstructured":"Torres-Flores, J. M., Reyes-Sandoval, A. & Salazar, M. I. Dengue vaccines: An update. BioDrugs 36, 325\u2013336. https:\/\/doi.org\/10.1007\/s40259-022-00531-z (2022).","journal-title":"BioDrugs"},{"key":"6974_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-023-00658-2","volume":"8","author":"SJ Thomas","year":"2023","unstructured":"Thomas, S. J. Is new dengue vaccine efficacy data a relief or cause for concern? npj Vaccines 8, 1\u20136. https:\/\/doi.org\/10.1038\/s41541-023-00658-2 (2023).","journal-title":"Npj Vaccines"},{"key":"6974_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715136","author":"JR Pinheiro","year":"2021","unstructured":"Pinheiro, J. R. et al. Comparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccines. Front. Immunol.. https:\/\/doi.org\/10.3389\/fimmu.2021.715136 (2021).","journal-title":"Front. Immunol."},{"key":"6974_CR47","doi-asserted-by":"publisher","first-page":"865180","DOI":"10.3389\/fimmu.2022.865180","volume":"13","author":"V Kaushik","year":"2022","unstructured":"Kaushik, V., Gupta, G. S. K., Kalra, L. R., Shaikh, U. & Cavallo, A. R. Immunoinformatics aided design and in-vivo validation of a cross-reactive peptide based multi-epitope vaccine targeting multiple serotypes of dengue virus. Front. Immunol. 13, 865180. https:\/\/doi.org\/10.3389\/fimmu.2022.865180 (2022).","journal-title":"Front. Immunol."},{"key":"6974_CR48","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.5935\/0103-5053.20140057","volume":"25","author":"AS de Oliveira","year":"2014","unstructured":"de Oliveira, A. S. et al. NS3 and NS5 proteins: Important targets for anti-dengue drug design. J. Braz. Chem. Soc. 25, 1759\u20131769. https:\/\/doi.org\/10.5935\/0103-5053.20140057 (2014).","journal-title":"J. Braz Chem. Soc."},{"key":"6974_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1248\/cpb.c17-00794","volume":"66","author":"Y-S Tian","year":"2018","unstructured":"Tian, Y-S., Zhou, Y., Takagi, T., Kameoka, M. & Kawashita, N. Dengue virus and its inhibitors: A brief review. Chem. Pharm. Bull. 66, 191\u2013206. https:\/\/doi.org\/10.1248\/cpb.c17-00794 (2018).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"6974_CR50","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.coi.2013.08.004","volume":"25","author":"GL Law","year":"2013","unstructured":"Law, G. L., Tisoncik-Go, J., Korth, M. J. & Katze, M. G. Drug repurposing: A better approach for infectious disease drug discovery? Curr. Opin. Immunol. 25, 588\u2013592. https:\/\/doi.org\/10.1016\/j.coi.2013.08.004 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"6974_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14656566.2022.2145883","volume":"24","author":"N Sabry","year":"2023","unstructured":"Sabry, N., Kamel, A. M., Cordie, A. & Esmat, G. Daclatasvir as a hepatitis C infection treatment option: An up-to-date evaluation. Expert Opin. Pharmacother. 24, 159\u2013170. https:\/\/doi.org\/10.1080\/14656566.2022.2145883 (2023).","journal-title":"Expert Opin. Pharmacother"},{"key":"6974_CR52","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1080\/14656566.2021.1943359","volume":"22","author":"P Balatow","year":"2021","unstructured":"Balatow, P., Sandlin, A. & Cory, T. J. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. Expert Opin. Pharmacother. 22, 1839\u20131846. https:\/\/doi.org\/10.1080\/14656566.2021.1943359 (2021).","journal-title":"Expert Opin. Pharmacother"},{"key":"6974_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.antiviral.2016.04.014","volume":"131","author":"F Kato","year":"2016","unstructured":"Kato, F. et al. Novel antiviral activity of Bromocriptine against dengue virus replication. Antiviral Res. 131, 141\u2013147. https:\/\/doi.org\/10.1016\/j.antiviral.2016.04.014 (2016).","journal-title":"Antiviral Res."},{"key":"6974_CR54","first-page":"751","volume":"41","author":"M Montgomery","year":"2016","unstructured":"Montgomery, M., Ho, N., Chung, E. & Marzella, N. Daclatasvir (Daklinza): A treatment option for chronic hepatitis C infection. Pharm. Ther. 41, 751\u2013755 (2016).","journal-title":"Pharm. Ther."},{"key":"6974_CR55","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889\u20131898. https:\/\/doi.org\/10.1056\/NEJMoa1402454 (2014).","journal-title":"N. Engl. J. Med."},{"key":"6974_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajg.2022.04.005","volume":"23","author":"MA Medhat","year":"2022","unstructured":"Medhat, M. A. et al. Sofosbuvir\/ledipasvir in combination or Nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Arab. J. Gastroenterol. 23, 165\u2013171. https:\/\/doi.org\/10.1016\/j.ajg.2022.04.005 (2022).","journal-title":"Arab. J. Gastroenterol."},{"key":"6974_CR57","doi-asserted-by":"publisher","first-page":"e2020102","DOI":"10.23750\/abm.v91i4.10877","volume":"91","author":"A Nourian","year":"2020","unstructured":"Nourian, A. et al. Efficacy and safety of sofosbuvir\/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed. 91, e2020102. https:\/\/doi.org\/10.23750\/abm.v91i4.10877 (2020).","journal-title":"Acta Biomed."},{"key":"6974_CR58","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cells10051052","volume":"10","author":"RH Pirzada","year":"2021","unstructured":"Pirzada, R. H., Haseeb, M., Batool, M., Kim, M. & Choi, S. Remdesivir and Ledipasvir among the FDA-Approved antiviral drugs have potential to inhibit SARS-CoV-2 replication. Cells 10, 1052. https:\/\/doi.org\/10.3390\/cells10051052 (2021).","journal-title":"Cells"},{"key":"6974_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40780-020-00162-y","volume":"6","author":"S Omotani","year":"2020","unstructured":"Omotani, S. et al. Drug-induced lung disease adverse effect with Ledipasvir acetonate\/sofosbuvir. J. Pharm. Health Care Sci. 6, 6. https:\/\/doi.org\/10.1186\/s40780-020-00162-y (2020).","journal-title":"J. Pharm. Health Care Sci."},{"key":"6974_CR60","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1080\/07391102.2020.1862707","volume":"40","author":"P Naresh","year":"2022","unstructured":"Naresh, P. et al. Targeting a conserved pocket (n-octyl-\u03b2-D-glucoside) on the dengue virus envelope protein by small bioactive molecule inhibitors. J. Biomol. Struct. Dyn. 40, 4866\u20134878. https:\/\/doi.org\/10.1080\/07391102.2020.1862707 (2022).","journal-title":"J. Biomol. Struct. Dyn."}],"updated-by":[{"DOI":"10.1038\/s41598-025-32110-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06974-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06974-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06974-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:52:07Z","timestamp":1766508727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06974-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6974"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06974-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-32110-x","URL":"https:\/\/doi.org\/10.1038\/s41598-025-32110-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animals rights"}}],"article-number":"27878"}}